GlassScriptPhysician profile
James Gerard Lennon
NPI 1124339338
$6,805.26
in general payments reported to CMS, 2019-2025
45 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2021: $3,441 · 2022: $114 · 2023: $746 · 2024: $1,190 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004 · Education: $57.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.95 |
| Education | $57.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $2,188.32 | 2021-2024 | Qinlock, Tgct |
| Jazz Pharmaceuticals INC. | $1,100.00 | 2021 | |
| Celgene Corporation | $251.40 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $217.44 | 2023-2025 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $214.30 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $205.86 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $193.20 | 2021-2024 | Ultomiris |
| Pfizer INC. | $192.58 | 2023-2025 | |
| Abbvie INC. | $167.04 | 2023-2025 | |
| Kite Pharma, INC. | $159.01 | 2019-2025 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $155.08 | 2022-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $147.84 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $135.49 | 2023-2025 | Imfinzi, Calquence, Enhertu |
| Array Biopharma INC | $122.76 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Glaxosmithkline, LLC. | $108.32 | 2024-2025 | Jemperli, Ojjaara, Blenrep |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $106.34 | 2023-2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $89.33 | 2023-2024 | Libtayo |
| Incyte Corporation | $85.68 | 2023-2025 | Jakafi, Monjuvi |
| Exelixis INC. | $82.48 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.81 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.57 | 2023-2025 | Fruzaqla, Ninlaro |
| Seagen INC. | $60.81 | 2023 | Adcetris, Tukysa |
| Genentech USA, INC. | $53.55 | 2023-2025 | Polivy, Venclexta, Tecentriq |
| Pharmaessentia USA Corporation | $49.01 | 2024 | Besremi |
| Gilead Sciences, INC. | $43.64 | 2024-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $42.50 | 2023-2024 | Krazati |
| Beigene USA, INC. | $41.58 | 2023-2024 | Brukinsa |
| Sobi, INC | $40.91 | 2023-2024 | |
| Morphosys, US INC. | $38.93 | 2023 | Monjuvi |
| Springworks Therapeutics, INC. | $36.96 | 2024-2025 | Ogsiveo |
| Lilly USA, LLC | $36.00 | 2024-2025 | Retevmo, Jaypirca, Verzenio |
| Genzyme Corporation | $29.88 | 2023 | |
| Eisai INC. | $29.59 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $27.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.01 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $22.81 | 2023 | Epkinly |
| Roche Diagnostics Corporation | $21.83 | 2025 | Inform Her2 Dual Ish Dna Probe Cocktail |
| Aveo Pharmaceuticals, INC. | $20.58 | 2023 | Fotivda |
| Emd Serono, INC. | $20.28 | 2023 | Bavencio |
| Myriad Genetic Laboratories, INC. | $15.62 | 2023 | Bracanalysis Cdx |
| Progenics Pharmaceuticals, INC. | $14.88 | 2024 | |
| Geron Corporation | $14.60 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $14.03 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $13.84 | 2025 | Pyrukynd |
| Caris Mpi, INC. | $13.49 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lennon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.